FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Research analysts at Roth Capital lifted their FY2024 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, November 5th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($1.00) for the year, up from their prior forecast of ($1.02). The consensus estimate for Nuvectis Pharma's current full-year earnings is ($1.05) per share. Roth Capital also issued estimates for Nuvectis Pharma's Q4 2024 earnings at ($0.25) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.94) EPS and FY2027 earnings at $1.64 EPS.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. During the same period in the prior year, the company earned ($0.37) EPS.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $21.00 target price on shares of Nuvectis Pharma in a research note on Tuesday, August 6th.

Nuvectis Pharma Trading Up 2.3 %

NASDAQ NVCT traded up $0.19 during trading hours on Thursday, hitting $8.34. 303,425 shares of the company's stock were exchanged, compared to its average volume of 103,790. The stock has a 50-day simple moving average of $6.81 and a 200 day simple moving average of $6.68. Nuvectis Pharma has a 1-year low of $5.85 and a 1-year high of $12.10. The firm has a market cap of $155.54 million, a price-to-earnings ratio of -6.59 and a beta of 0.41.

Institutional Investors Weigh In On Nuvectis Pharma

A number of hedge funds have recently added to or reduced their stakes in NVCT. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Nuvectis Pharma in the second quarter valued at approximately $58,000. Nations Financial Group Inc. IA ADV acquired a new stake in Nuvectis Pharma in the third quarter valued at approximately $63,000. Baxter Bros Inc. acquired a new stake in Nuvectis Pharma in the second quarter valued at approximately $79,000. GSA Capital Partners LLP boosted its position in shares of Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company's stock valued at $315,000 after buying an additional 1,790 shares during the last quarter. Finally, Iridian Asset Management LLC CT purchased a new position in shares of Nuvectis Pharma during the third quarter valued at approximately $348,000. Institutional investors and hedge funds own 96.77% of the company's stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.